Takao Asai

Takao Asai

Auto-generated profile, based on publicly available information

Takao Asai

Department of Clinical Engineering, Faculty of Medical Science, Juntendo University, Chiba, Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2014 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
TATakao Asai
Takao Asai
ELErnesto Loza
Ernesto Loza
GRGuido Villa-Gomez Roig
Guido Villa-Gomez Roig
YAYoichi Ajioka
Yoichi Ajioka
YTYasuo Tsuchiya
Yasuo Tsuchiya
KNKazutoshi Nakamura
Kazutoshi Nakamura
Although genetic characteristics are considered to be a factor influencing the geographic variation in the prevalence of gallbladder cancer (GBC), they have not been well studied in Bolivia, which has a high prevalence rate of GBC. The purpose of this study was to examine the frequency of TP53 and K-ras mutations in Bolivian patients with GBC and to compare them with our previous data obtained in other high-GBC-prevalence countries, namely Japan, Chile, and Hungary. DNA was extracted from cancer sites in paraffin-embedded tissue from 36 patients using a microdissection technique. TP53 mutations at exons 5 to 8 and K-ras mutations at codons 12, 13 and 61 were examined using direct sequencing techniques. The data obtained were compared with those in the other high-GBC-prevalence countries. Of the 36 patients, 18 (50.0%) had a TP53 mutation (one mutation in each of 17 patients and three mutations in one patient), and only one (2.8%) had a K-ras mutation. Of the 20 TP53 mutations, 12 were of the transition type (60.0%). This rate was significantly lower than that in Chile (12/12, P<0.05). In addition, three mutations were of the CpG transition type (15.0%), which is a feature of endogenous mutation. All three were found in the hot spot region of the TP53 gene. In contrast, G:C to T:A transversion was found in Bolivia, suggesting the presence of exogenous carcinogens. Our findings suggest that the development of GBC in Bolivia is associated with both exogenous carcinogens and endogenous mechanisms. The identification of an environmental risk factor for GBC is needed to confirm these findings.

6 December 2016 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
TATakao Asai
Takao Asai
CVClaudia Còrdova Vidal
Claudia Còrdova Vidal
WSWilma Strauss
Wilma Strauss
TIToshikazu Ikoma
Toshikazu Ikoma
KEKazuo Endoh
Kazuo Endoh
MYMasaharu Yamamoto
Masaharu Yamamoto
Bolivia is one of the countries with a high intestinal helminth and protozoan infection rate. Despite the high prevalence of the parasitic infection, nationwide preventive measures for Bolivian children have not yet been implemented. We evaluated the effect of mass stool examination and treatment as a strategy for decreasing the infection rate. This study was conducted between 2013 and 2015 in children aged 2–18 years. A total of 2,033 stool samples (575 in 2013, 815 in 2014 and 642 in 2015) were collected and examined using the formalin-ether medical sedimentation method. As an anthelminthic medicine, nitazoxanide was given to all infected children within 2 months post-examination, each year. The effect of mass stool examination and treatment was evaluated based on the changes in the overall or individual parasitic infection rates during the study period. The overall parasitic infection rate decreased significantly from 65.2% in 2013 to 43.0% in 2015; a 22.2 percentage point decrease (P<0.001). Protozoan infection accounted for a large portion of the parasitic infections, in the following rates: 62.4% in 2013, 49.3% in 2014, and 41.0% in 2015. The rate of the most common helminth infection, Hymenolepis nana, decreased significantly from 9.0% in 2013 to 6.4% in 2014 to 3.4% in 2015 (P<0.001). Prevalence of the most common pathogenic protozoan infection, Entamoeba histolytica, decreased significantly from 19.0% in 2013 to 3.0% in 2015 (P<0.001). Conversely, the rate of Giardia intestinalis increased significantly from 16.5% in 2013 to 21.2% in 2015 (P<0.01). Mass stool examination and treatment for intestinal helminth and protozoan infections was effective for decreasing the overall parasitic infection rate in the study population, excluding Giardia intestinalis. Further studies on the long-term effect of mass stool examination and treatment for decreasing all intestinal parasitic infection rates in Bolivian children are needed. Intestinal helminth and protozoan (parasitic) infections are found mainly in areas with warm, humid climates and in many developing countries. Bolivia currently has high parasite infection rates, including intestinal helminth and protozoan infections. Despite the high prevalence of parasitic infections, nationwide preventive measures for Bolivian children have not yet been implemented. Soil-transmitted helminth infection rates in Japan decreased sharply through practice of health education, mass stool examination and treatment. We investigated the effects of mass stool examination and treatment on parasitic infection rates in Bolivian children. Mass stool examination was performed using the formalin-ether medical sedimentation method between 2013 and 2015, and all infected children were administrated anthelminthic medicine within 2 months post-examination. During the study period, the overall infection rate decreased significantly, but Giardia intestinalis infection rate increased. This may have been related to the interval between treatment and examination. To decrease infection rates for all parasites, the treatment should be performed once or twice a year. Our results suggest that a program of mass stool examination and treatment could effectively reduce the overall parasite-infection rate in Bolivian children.

1 December 2019 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
TATakao Asai
Takao Asai
YTYasuo Tsuchiya
Yasuo Tsuchiya
KMKumudesh Mishra
Kumudesh Mishra
ABAnu Behari
Anu Behari
PSPooja Shukla
Pooja Shukla
KNKazutoshi Nakamura
Kazutoshi Nakamura
Background: Carcinogen metabolism pathway and tumor suppressor gene polymorphisms have been reported to be associated with increased gallbladder cancer risk. However, the association of genetic variants and gallbladder cancer risk in Indians are not well studied. We examined whether genetic polymorphisms of metabolic enzymes cytochrome P450 1A1 and glutathione S-transferase and tumor suppressor gene p53 (TP53) are associated with an increased risk of gallbladder cancer in North Indians. Methods: This hospital-based case-control study was conducted in 96 gallbladder cancer patients with gallstones (cases) and 93 cholelithiasis patients (controls) at the Sanjay Gandhi Postgraduate Institute of Medical Sciences in Lucknow, India from July 2014 through May 2017. Genomic DNA was extracted from white blood cells of each patient using a simple salting-out procedure. The genotypic frequencies of CYP1A1 rs4646903, CYP1A1 rs1048943, and TP53 rs1042522 polymorphisms were investigated using TaqMan SNP Genotyping Assay and GSTM1 and GSTT1 polymorphisms were analyzed using the multiplex PCR assay. Results: The frequency of CC genotype of TP53 rs1042522 polymorphism was 27.1% (26/96) in cases and 12.9% (12/93) in controls. The CC genotype was associated with an increased risk of gallbladder cancer in North Indians (age- and sex-adjusted odds ratio, 2.81; 95% confidence interval, 1.19–6.61; P = 0.02). No significant differences in genotypic and allelic frequencies of the metabolic pathway gene polymorphisms were found between cases and controls. Conclusions: Our data provide preliminary evidence that the CC genotype of the TP53 rs1042522 polymorphism may be associated with an increased risk of gallbladder cancer in North Indians. Asian Pacific Journal of Cancer Prevention (APJCP)

2 September 2025
Verified
Other
Open access
TATakao Asai
Takao Asai
TYTaiki Yamaji
Taiki Yamaji
SNShiori Nakano
Shiori Nakano
NSNorie Sawada
Norie Sawada
MIManami Inoue
Manami Inoue
MIMotoki Iwasaki
Motoki Iwasaki
Although several retrospective studies have investigated the association of TP53 rs1042522 and ApoB rs693 with the risk of biliary tract cancer (BTC), results have been inconsistent. In this study, to provide evidence from a prospective study, we analyzed the association of these two genetic polymorphisms with BTC risk using data from the Japan Public Health Center-based Prospective Study. We conducted a case–cohort study with 152 BTC cases and 12,159 subcohort subjects and estimated HRs and 95% confidence intervals (CI) using a weighted Cox proportional hazards model. TP53 rs1042522 showed a statistically significant association with the risk of BTC (HR, 1.89; 95% CI, 1.27–2.82, in the recessive genetic model), whereas ApoB rs693 showed no apparent association. Of interest, TP53 rs1042522 seemed to be associated with BTC risk in a recessive model, but not in a dominant model. On comparison of three BTC subtypes, TP53 rs1042522 seemed to be associated with the incidence of gallbladder cancer and extrahepatic bile duct cancer (HR, 2.21; 95% CI, 1.14–4.28 and HR, 1.97; 95% CI, 1.00–3.88, respectively) but showed only a nonsignificant association with intrahepatic bile duct cancer (HR, 1.58; 95% CI, 0.63–3.96). In this prospective case–cohort study, we found evidence to support an association between the TP53 rs1042522 polymorphism and the risk of BTC. The null finding for ApoB rs693 might be due to the extremely low T-allele frequency (4.4%) in the study population.Prevention Relevance:This prospective study highlights the effect of TP53 rs1042522 on BTC risk in Japanese individuals. Identifying carriers of the high-risk CC genotype may facilitate targeted surveillance and early detection strategies, potentially reducing mortality and improving outcomes. Further large-scale studies are required to clarify environmental interactions and optimize prevention.

2 May 2025 in Cancer Prevention Research
Verified
Journal Article
Closed access
TATakao Asai
Takao Asai
TYTaiki Yamaji
Taiki Yamaji
SNShiori Nakano
Shiori Nakano
NSNorie Sawada
Norie Sawada
MIManami Inoue
Manami Inoue
MIMotoki Iwasaki
Motoki Iwasaki
Although several retrospective studies have investigated the association of TP53 rs1042522 and ApoB rs693 with the risk of biliary tract cancer (BTC), results have been inconsistent. In this study, to provide evidence from a prospective study, we analyzed the association of these two genetic polymorphisms with BTC risk using data from the Japan Public Health Center-based Prospective Study. We conducted a case–cohort study with 152 BTC cases and 12,159 subcohort subjects and estimated HRs and 95% confidence intervals (CI) using a weighted Cox proportional hazards model. TP53 rs1042522 showed a statistically significant association with the risk of BTC (HR, 1.89; 95% CI, 1.27–2.82, in the recessive genetic model), whereas ApoB rs693 showed no apparent association. Of interest, TP53 rs1042522 seemed to be associated with BTC risk in a recessive model, but not in a dominant model. On comparison of three BTC subtypes, TP53 rs1042522 seemed to be associated with the incidence of gallbladder cancer and extrahepatic bile duct cancer (HR, 2.21; 95% CI, 1.14–4.28 and HR, 1.97; 95% CI, 1.00–3.88, respectively) but showed only a nonsignificant association with intrahepatic bile duct cancer (HR, 1.58; 95% CI, 0.63–3.96). In this prospective case–cohort study, we found evidence to support an association between the TP53 rs1042522 polymorphism and the risk of BTC. The null finding for ApoB rs693 might be due to the extremely low T-allele frequency (4.4%) in the study population. Prevention Relevance: This prospective study highlights the effect of TP53 rs1042522 on BTC risk in Japanese individuals. Identifying carriers of the high-risk CC genotype may facilitate targeted surveillance and early detection strategies, potentially reducing mortality and improving outcomes. Further large-scale studies are required to clarify environmental interactions and optimize prevention.

2 September 2025
Verified
Other
Open access
TATakao Asai
Takao Asai
TYTaiki Yamaji
Taiki Yamaji
SNShiori Nakano
Shiori Nakano
NSNorie Sawada
Norie Sawada
MIManami Inoue
Manami Inoue
MIMotoki Iwasaki
Motoki Iwasaki
Number of biliary tract cancer cases based on the International Classification of Diseases for Oncology, third Edition.